Cargando…
Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients
The evolution of snake venoms resulted in multigene toxin families that code for structurally similar isoforms eventually harboring distinct functions. PLA(2)s are dominant toxins in viper venoms, and little is known about the impact of their diversity on human envenomings and neutralization by anti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414272/ https://www.ncbi.nlm.nih.gov/pubmed/36006204 http://dx.doi.org/10.3390/toxins14080543 |
_version_ | 1784775950381088768 |
---|---|
author | Sousa, Leijiane F. Freitas, Amanda P. Cardoso, Bruna L. Del-Rei, Tiago H. M. Mendes, Vanessa A. Oréfice, Daniele P. Rocha, Marisa M. T. Prezoto, Benedito C. Moura-da-Silva, Ana M. |
author_facet | Sousa, Leijiane F. Freitas, Amanda P. Cardoso, Bruna L. Del-Rei, Tiago H. M. Mendes, Vanessa A. Oréfice, Daniele P. Rocha, Marisa M. T. Prezoto, Benedito C. Moura-da-Silva, Ana M. |
author_sort | Sousa, Leijiane F. |
collection | PubMed |
description | The evolution of snake venoms resulted in multigene toxin families that code for structurally similar isoforms eventually harboring distinct functions. PLA(2)s are dominant toxins in viper venoms, and little is known about the impact of their diversity on human envenomings and neutralization by antivenoms. Here, we show the isolation of three distinct PLA(2)s from B. atrox venom. FA1 is a Lys-49 homologue, and FA3 and FA4 are catalytic Asp-49 PLA(2)s. FA1 and FA3 are basic myotoxic proteins, while FA4 is an acid non-myotoxic PLA(2). FA3 was the most potent toxin, inducing higher levels of edema, inflammatory nociception, indirect hemolysis, and anticoagulant activity on human, rat, and chicken plasmas. FA4 presented lower anticoagulant activity, and FA1 had only a slight effect on human and rat plasmas. PLA(2)s presented differential reactivities with antivenoms, with an emphasis on FA3, which was not recognized or neutralized by the antivenoms used in this study. Our findings reveal the functional and antigenic diversity among PLA(2)s from B. atrox venom, highlighting the importance of assessing venom variability for understanding human envenomations and treatment with antivenoms, particularly evident here as the antivenom fails to recognize FA3, the most active multifunctional toxin described. |
format | Online Article Text |
id | pubmed-9414272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94142722022-08-27 Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients Sousa, Leijiane F. Freitas, Amanda P. Cardoso, Bruna L. Del-Rei, Tiago H. M. Mendes, Vanessa A. Oréfice, Daniele P. Rocha, Marisa M. T. Prezoto, Benedito C. Moura-da-Silva, Ana M. Toxins (Basel) Article The evolution of snake venoms resulted in multigene toxin families that code for structurally similar isoforms eventually harboring distinct functions. PLA(2)s are dominant toxins in viper venoms, and little is known about the impact of their diversity on human envenomings and neutralization by antivenoms. Here, we show the isolation of three distinct PLA(2)s from B. atrox venom. FA1 is a Lys-49 homologue, and FA3 and FA4 are catalytic Asp-49 PLA(2)s. FA1 and FA3 are basic myotoxic proteins, while FA4 is an acid non-myotoxic PLA(2). FA3 was the most potent toxin, inducing higher levels of edema, inflammatory nociception, indirect hemolysis, and anticoagulant activity on human, rat, and chicken plasmas. FA4 presented lower anticoagulant activity, and FA1 had only a slight effect on human and rat plasmas. PLA(2)s presented differential reactivities with antivenoms, with an emphasis on FA3, which was not recognized or neutralized by the antivenoms used in this study. Our findings reveal the functional and antigenic diversity among PLA(2)s from B. atrox venom, highlighting the importance of assessing venom variability for understanding human envenomations and treatment with antivenoms, particularly evident here as the antivenom fails to recognize FA3, the most active multifunctional toxin described. MDPI 2022-08-08 /pmc/articles/PMC9414272/ /pubmed/36006204 http://dx.doi.org/10.3390/toxins14080543 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sousa, Leijiane F. Freitas, Amanda P. Cardoso, Bruna L. Del-Rei, Tiago H. M. Mendes, Vanessa A. Oréfice, Daniele P. Rocha, Marisa M. T. Prezoto, Benedito C. Moura-da-Silva, Ana M. Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title | Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title_full | Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title_fullStr | Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title_full_unstemmed | Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title_short | Diversity of Phospholipases A(2) from Bothrops atrox Snake Venom: Adaptive Advantages for Snakes Compromising Treatments for Snakebite Patients |
title_sort | diversity of phospholipases a(2) from bothrops atrox snake venom: adaptive advantages for snakes compromising treatments for snakebite patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414272/ https://www.ncbi.nlm.nih.gov/pubmed/36006204 http://dx.doi.org/10.3390/toxins14080543 |
work_keys_str_mv | AT sousaleijianef diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT freitasamandap diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT cardosobrunal diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT delreitiagohm diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT mendesvanessaa diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT oreficedanielep diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT rochamarisamt diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT prezotobeneditoc diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients AT mouradasilvaanam diversityofphospholipasesa2frombothropsatroxsnakevenomadaptiveadvantagesforsnakescompromisingtreatmentsforsnakebitepatients |